Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 22 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 10730949

    Method of treating PVNS with anti-CSF1R antibodies

    Five Prime Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  2. US 10723787

    Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  3. US 10723777

    Peptide having anti-obesity and anti-diabetes efficacy and use thereof

    CAREGEN CO., LTD. · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  4. US 10722594

    Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

    ADC THERAPEUTICS SA · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  5. US 10723764

    Anti-microbial peptides and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jul 28, 2020 · Expires Jul 23, 2040

    granted

  6. US 10711068

    Anti-CD133 monoclonal antibodies and related compositions and methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted

  7. US 10702525

    Pyrimidine derivatives as anti-diabetic agents

    UNITED ARAB EMIRATES UNIVERSITY · Granted Jul 7, 2020 · Expires Jul 2, 2040

    granted

  8. US 10689392

    Anti-cancer compounds targeting ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  9. US 10689456

    Anti-CD70 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  10. US 10683347

    Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

    The Regents of the University of California · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted

  11. US 10683354

    Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted

  12. US 10675245

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Pacira Pharmaceuticals, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  13. US 10676480

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  14. US 10669337

    Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

    CytomX Therapeutics, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  15. US 10669339

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  16. US 10640558

    Anti-IL-25 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted

  17. US 10639303

    Alkaloids and their preparation and application as anti-HSV-1 agents

    OCEAN UNIVERSITY OF CHINA · Granted May 5, 2020 · Expires Apr 30, 2040

    granted

  18. US 10639348

    Peptides with anti-cancer activity

    IDP DISCOVERY PHARMA, S.L. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted

  19. US 10632194

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted

  20. US 10633434

    Anti-C5 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted

  21. US 10626145

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted

  22. US 10624878

    Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Granted Apr 21, 2020 · Expires Apr 16, 2040

    granted

  23. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  24. US 10617642

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Pacira Pharmaceuticals, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.